Analysts’ Weekly Ratings Changes for Maplight Therapeutics (MPLT)

A number of research firms have changed their ratings and price targets for Maplight Therapeutics (NASDAQ: MPLT):

• 7/24/2026 – Maplight Therapeutics was given a new $43.00 price target by Canaccord Genuity Group Inc..
• 7/21/2026 – Maplight Therapeutics had its price target raised by UBS Group AG from $48.00 to $52.00. They now have a “buy” rating on the stock.
• 7/20/2026 – Maplight Therapeutics is now covered by BMO Capital Markets. They set an “outperform” rating and a $46.00 price target on the stock.
• 7/20/2026 – Maplight Therapeutics was upgraded by BMO Capital Markets to “strong-buy”.
• 7/13/2026 – Maplight Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/10/2026 – Maplight Therapeutics was upgraded by Wolfe Research to “strong-buy”.
• 7/10/2026 – Maplight Therapeutics had its price target raised by Needham & Company LLC from $42.00 to $45.00. They now have a “buy” rating on the stock.
• 6/24/2026 – Maplight Therapeutics is now covered by Raymond James Financial, Inc.. They set a “strong-buy” rating and a $46.00 price target on the stock.
• 6/24/2026 – Maplight Therapeutics was upgraded by Raymond James Financial, Inc. to “strong-buy”.
• 6/23/2026 – Maplight Therapeutics had its price target lowered by Craig Hallum from $43.00 to $40.00. They now have a “buy” rating on the stock.
• 6/22/2026 – Maplight Therapeutics had its “buy” rating reaffirmed by Benchmark Co..
• 6/22/2026 – Maplight Therapeutics had its “buy” rating reaffirmed by HC Wainwright.
• 6/22/2026 – Maplight Therapeutics had its price target raised by Needham & Company LLC from $37.00 to $42.00. They now have a “buy” rating on the stock.
• 6/1/2026 – Maplight Therapeutics had its price target raised by Stifel Nicolaus from $28.00 to $36.00. They now have a “buy” rating on the stock.
• 5/28/2026 – Maplight Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $45.00 price target on the stock.
• 5/26/2026 – Maplight Therapeutics is now covered by UBS Group AG. They set a “buy” rating and a $48.00 price target on the stock.
• 5/26/2026 – Maplight Therapeutics was upgraded by UBS Group AG to “strong-buy”.

Insider Buying and Selling

In related news, CFO Vishwas Setia sold 10,564 shares of the stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $28.24, for a total transaction of $298,327.36. Following the sale, the chief financial officer directly owned 356,256 shares in the company, valued at $10,060,669.44. This represents a 2.88% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider James Woodruff Lillie sold 24,811 shares of the firm’s stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $28.76, for a total value of $713,564.36. Following the sale, the insider directly owned 243,450 shares of the company’s stock, valued at $7,001,622. This represents a 9.25% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 495,244 shares of company stock valued at $14,079,461. 3.80% of the stock is currently owned by insiders.

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.